NovaBay Pharmaceuticals Inc
NBY
View Detailed Chart
1.820USD
-0.120-6.19%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
10.59MMarket Cap
4.57P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-6.19%
5 Days
-29.73%
1 Month
+203.33%
6 Months
+202.07%
Year to Date
+202.83%
1 Year
+266.27%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.850
Target Price
-56.19%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.78M.
Overvalued
The company’s latest PE is 0.45, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.43M shares, increasing 12.87% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.07.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
Ticker SymbolNBY
CompanyNovaBay Pharmaceuticals Inc
CEOMr. David E. Lazar
Websitehttps://novabay.com/
Related Instruments
-1.43%
+1.17%
+0.22%
+0.52%
-1.03%
-0.73%
-0.02%
+3.47%
+0.41%
-0.50%
-0.08%
-1.03%
-1.27%
+1.19%
+0.92%
-0.87%
-0.23%
-0.83%
-1.12%
+0.31%
